{"id":11191,"date":"2020-11-16T13:27:43","date_gmt":"2020-11-16T07:57:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11191"},"modified":"2021-07-29T14:49:15","modified_gmt":"2021-07-29T09:19:15","slug":"epilepsy-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market","title":{"rendered":"Ever-evolving Market Dynamics of Epilepsy \u2013 a silver lining!"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a57b6107f8e4\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a57b6107f8e4\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\/#Potential_and_growth_of_the_current_market\" >Potential and growth of the current market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\/#Cannabidiol_Performance_and_Competition_till_now_Why_is_Epidiolex_such_a_hit_in_the_market\" >Cannabidiol Performance and Competition till now? Why is Epidiolex such a hit in the market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\/#UCB_Pharma_The_star_player_in_the_epilepsy_market\" >UCB Pharma: The star player in the epilepsy market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\/#What_about_the_other_ultra-rare_epilepsy_indications\" >What about the other ultra-rare epilepsy indications?<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Potential_and_growth_of_the_current_market\"><\/span><strong>Potential and growth of the current market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects. The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of them were novel therapies (<a href=\"https:\/\/www.delveinsight.com\/blog\/medical-marijuana-market\/\" target=\"_blank\" rel=\"noreferrer noopener\">Epidiolex<\/a>), while the rest of them were enhanced versions or better formulations of the already existing classes (Xcopri, Valtoco, Sympazan, and Nayzilam). It is crucial to understand that most of these medications have been approved as adjuvant therapies in combination with already existing AEDs. Medications like Nayzilam, Sympazan, and Valtoco are benzodiazepines, a drug class that has been used to treat epilepsy for decades. These improved formulations are launched in expectation of meeting the current unmet needs \u2013 side effects and risk of drug dependence \u2013 while becoming the best versions of the already existing classes.&nbsp;<\/p>\n\n\n\n<p><strong>Epilepsy is an umbrella indication<\/strong> encompassing numerous seizure types. Both the current key players as well the emerging players are focusing on the development activity specific to each <strong>Epilepsy Indication <\/strong>(<a href=\"https:\/\/www.delveinsight.com\/report-store\/lennox-gastaut-syndrome-market\" target=\"_blank\" rel=\"noreferrer noopener\">Lennox\u2013Gastaut syndrome<\/a> [LGS], Dravet syndrome, West syndrome, drug resistance epilepsy, developmental and epileptic encephalopathies, CDKL5 deficiency disorder, PCDH-19, and status epilepticus), or epilepsy types based on <strong>seizures<\/strong> (acute repetitive seizures, seizure clusters, partial seizures, refractory seizures).&nbsp; <strong>Aquestive Therapeutics<\/strong> is one of the leading specialty pharma players in developing oral films using its novel <strong>PharmFilm technology<\/strong>. The company has already received approval for <strong>Sympazan<\/strong>, which is the first oral film formulation of clobazam targeting the seizures associated with LGS patients, including children. The company developed this medication after realizing an unmet need of LGS patients having a tough time swallowing pills and suspensions. In addition to Sympazan, in February 2020, FDA accepted Aquestive\u2019s NDA for <strong>Libervant<\/strong>, another Buccal Film for managing seizure clusters in refractory epilepsy, and has a much larger target pool when compared to Sympazan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cannabidiol_Performance_and_Competition_till_now_Why_is_Epidiolex_such_a_hit_in_the_market\"><\/span><strong>Cannabidiol Performance and Competition till now? Why is Epidiolex such a hit in the market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>GW Pharma\u2019s Epidiolex<\/strong> (Epidyolex in Europe), the only cannabidiol in the epilepsy market for patients suffering from LGS and Dravet Syndrome, is still being evaluated in West syndrome trials. The drug has already achieved a milestone generating high sales in the United States and Europe recently and has geared up for more achievements in the future. In 2018, the FDA also approved Diacomit combination therapy fo<a href=\"https:\/\/www.delveinsight.com\/blog\/dravet-syndrome-market\/\" target=\"_blank\" rel=\"noreferrer noopener\">r Dravet syndrome<\/a>; however, unlike Epidiolex, <em>Diacomit\u2019s entry seemed lukewarm<\/em>. So, what makes Epidiolex a success? GW pharma has been quite lucky on this part, as most of the states in the US have loosened up their laws concerning medical marijuana by increasing their access to the medication, making them more attractive for parents of Dravet patients. Therefore, Epidiolex is expected to take the lion\u2019s share in the estimated <a href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market\" target=\"_blank\" rel=\"noreferrer noopener\">epilepsy market<\/a> of USD 2,166 million in 2020, in the US, as per DelveInsight\u2019s forecast analysis. Additionally, Epidiolex has also found its way to Japan\u2019s pharma market, where cannabis has been illegal for decades, by receiving approval for clinical trials last year in 2019.<\/p>\n\n\n\n<p>With the recent approval of Zogenix in July 2020 to treat Dravet syndrome, <strong>Fintepla <\/strong>is expected to become a rival to both Epidiolex and Diacomit. However, the premium pricing of Fintepla, along with its availability under the risk evaluation and mitigation strategy (REMS) program, might be a hindrance to its acceptance. Approved for Dravet Syndrome, Fintepla is being evaluated in clinical trials as adjunctive therapy in several other types such as photosensitive&nbsp;epilepsy, Lennox\u2013Gastaut syndrome, and <strong>epileptic encephalopathy.<\/strong><\/p>\n\n\n\n<p>In addition to Epidiolex, <strong>Zynerba <\/strong>is evaluating a permeation enhanced <strong>cannabidiol transdermal gel <\/strong>for <strong>developmental and epileptic encephalopathies (DEEs<\/strong>) in pediatric patients in Phase III clinical trials. The company is quite consistent in its approach and has concluded several meetings with the FDA to discuss the further clinical development of its gel. From the perspective of the potential pool, DEE is an umbrella term for several infants and childhood related epilepsies such as <strong>Ohtahara syndrome<\/strong>, <strong>Landau\u2013Kleffner syndrome<\/strong>, <strong>infantile spasms<\/strong>,<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\" target=\"_blank\" rel=\"noreferrer noopener\">Dravet syndrome<\/a><\/strong>, <strong>LGS<\/strong>, and a few more. Additionally, a unique oral formulation of cannabidiol is being evaluated by Insys therapeutics in the <strong>childhood absence of epilepsy<\/strong> and <strong>infantile spasms.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"UCB_Pharma_The_star_player_in_the_epilepsy_market\"><\/span><strong>UCB Pharma: The star player in the epilepsy market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Another Key player with an immensely robust portfolio in the epilepsy market is <strong>UCB pharma<\/strong>. Its already existing medications such as <strong>Briviact<\/strong>, <strong>Vimpat<\/strong>, and <strong>Keppra<\/strong> are doing wonders as monotherapies or adjunctive therapies, and the company has further strengthened its position with the launch of <strong>Nayzilam<\/strong>, as the patent of its former three drugs will soon get expired. Nayzilam (midazolam) is a rescue treatment offered in the form of a nasal spray to manage patients with seizure clusters. This spray can be administered anywhere the seizure cluster strikes, therefore providing ease of administration and preventing deterioration of condition before the patient could be taken to the hospital. Following the approval of Nayzilam in December 2019, Neurelis, Inc. announced the commercial availability of its nasal spray, Valtoco (diazepam), in March 2020. Valtoco is expected to provide stiff competition to Nayzilam, considering the nearby launch dates, the same mode of administration, and exactly the same target patient pool of <strong>seizure clusters <\/strong>or<strong> acute repetitive seizures<\/strong>.<\/p>\n\n\n\n<p><strong>UCB Pharma<\/strong>\u2019s leadership has been underlined with the recent addition of <strong>Staccato Alprazolam <\/strong>to its pipeline. The drug is a single-use rescue treatment to rapidly terminate an active epileptic seizure, providing a potential solution in ~20\u201330% of the total epilepsy pool. The resulting patient pool will be quite large, as Delveinsight estimates <strong>7,303,648 epilepsy patients in the 7 Major Markets<\/strong> in the year 2020. However, the diagnosed pool is slightly lesser than these patients. UCB has added this Phase II investigational drug-device combination after the acquisition of Engage Therapeutics, the originator of this hand-held inhaler, and is having expectations of increasing its patient-centric growth strategy.<\/p>\n\n\n\n<p>Another potential pool that UCB has targeted is <strong>highly drug-resistant focal&nbsp;epilepsy <\/strong>or <strong>epileptic patients<\/strong> with <strong>focal onset seizures. <\/strong>Although the drug failed to meet its primary endpoint in its recent Phase IIb trial, the company is determined to further analyze the data for a better understanding of results.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_about_the_other_ultra-rare_epilepsy_indications\"><\/span><strong>What about the other ultra-rare epilepsy indications?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>DelveInsight <\/strong>has analyzed the unmet need in the ultra-rare epilepsy treatment regimen too, wherein <strong>Takeda<\/strong> and <strong>Marinus Pharma <\/strong>are market leaders.<strong> Takeda\/Ovid\u2019s<\/strong> Soticlestat is another potential emerging therapy in the pipeline targeting indications such as Dravet syndrome, LGS, along with ultra-rare epilepsies, including<strong> Dup15q syndrome<\/strong>, <strong>CDKL5 deficiency disorder, <\/strong>and<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\" target=\"_blank\" rel=\"noreferrer noopener\">DEEs<\/a>. <\/strong>Data from recent ARCADE and ENDYMION study has proved early activity and seizure frequency reduction across multiple rare epilepsies; these positive results have led <strong>Takeda\/Ovid Therapeutics <\/strong>to push the drug into the final developmental stage. Additionally, Marinus Pharma is excited as its <strong>Ganaxolone<\/strong> recently received<strong> rare pediatric disease (RPD) designation <\/strong>for the treatment of<strong> CDKL5 deficiency disorder (CDD) <\/strong>and is heading its way toward advancing the drug towards its final development stage. One of the noteworthy findings of Takeda and Marinus is that both are also targeting a life-threatening occurrence of continued or intermittent seizures lasting more than 5 min, which is known as <strong>Status Epilepticus<\/strong>, an indication with a substantial unmet need.<\/p>\n\n\n\n<p>Considering a vast pipeline and already existing treatments, DelveInsight has estimated the current 2020 market of epilepsy to be <strong>2,769 USD million<\/strong> in the 7MM. Furthermore, DelveInsight has also deeply analyzed the competition among many more emerging therapies (not described above), the impact of all the emerging therapies on the current market, detailed attribute analysis, in-depth market insights, market forecast of <strong>10+ emerging drugs,<\/strong> and Line-wise market coverage of the current treatment along with revenue of major approved medications of epilepsy in its recently updated \u201c<strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market\" target=\"_blank\" rel=\"noreferrer noopener\">Epilepsy \u2013 Market Insights Epidemiology and Market Forecast \u2013 2030<\/a><\/strong>&#8221; report and forecasting model.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Potential and growth of the current market The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects. The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11198,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2885,1494,16744,2886],"industry":[17225],"therapeutic_areas":[17238,17245,17234],"class_list":["post-11191","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-epidiolex","tag-epilepsy","tag-epilepsy-market","tag-seizures","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Epilepsy Market | Key companies in Epilepsy Market | DelveInsight<\/title>\n<meta name=\"description\" content=\"The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of them were novel therapies (Epidiolex), while the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epilepsy Market | Key companies in Epilepsy Market | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of them were novel therapies (Epidiolex), while the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/epilepsy-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T07:57:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-29T09:19:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Epilepsy Market | Key companies in Epilepsy Market | DelveInsight","description":"The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of them were novel therapies (Epidiolex), while the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market","og_locale":"en_US","og_type":"article","og_title":"Epilepsy Market | Key companies in Epilepsy Market | DelveInsight","og_description":"The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of them were novel therapies (Epidiolex), while the...","og_url":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-11-16T07:57:43+00:00","article_modified_time":"2021-07-29T09:19:15+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Ever-evolving Market Dynamics of Epilepsy \u2013 a silver lining!","datePublished":"2020-11-16T07:57:43+00:00","dateModified":"2021-07-29T09:19:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market"},"wordCount":1299,"commentCount":0,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market.jpg","keywords":["Epidiolex","Epilepsy","Epilepsy market","Seizures"],"articleSection":["Articles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.delveinsight.com\/blog\/epilepsy-market#respond"]}],"copyrightYear":"2020","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market","url":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market","name":"Epilepsy Market | Key companies in Epilepsy Market | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market.jpg","datePublished":"2020-11-16T07:57:43+00:00","dateModified":"2021-07-29T09:19:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The epilepsy market has witnessed several approvals in the last 3\u20134 years, few of them were novel therapies (Epidiolex), while the...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/epilepsy-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/epilepsy-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market.jpg","width":772,"height":482,"caption":"Epilepsy Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/11\/11170442\/Epilepsy-Market-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epidiolex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epilepsy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epilepsy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Seizures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Epidiolex<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy market<\/span>","<span class=\"advgb-post-tax-term\">Seizures<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 16, 2020","modified":"Updated on Jul 29, 2021"},"absolute_dates_time":{"created":"Posted on Nov 16, 2020 1:27 pm","modified":"Updated on Jul 29, 2021 2:49 pm"},"featured_img_caption":"Epilepsy Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11191"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11191\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11198"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11191"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11191"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}